CTOs on the Move

EnviroLogix

www.envirologix.com

 
Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.envirologix.com
  • 500, Riverside Industrial Parkway
    Portland, ME USA 04103
  • Phone: 866.408.4597

Executives

Name Title Contact Details

Similar Companies

genscript

genscript is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BNBI

Managed by Battelle National Biodefense Institute (BNBI) as a Federally Funded Research and Development Center (FFRDC), National Biodefense Analysis and Countermeasures Center is the first laboratory built for DHS – a national resource to understand th...

Scorpion Therapeutics

Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

Lygos

Lygos employs cutting edge synthetic biology techniques to generate microbial catalysts to convert agricultural feedstocks into fine and commodity chemicals. Our robust high throughput screening and strain construction facilitates the rapid optimization of pathways to convert cheap and renewable feedstock to high value chemicals.